Understanding allosteric modulation and biased signalling at Family B GPCRs

B家族GPCRs是治疗骨质疏松症、高钙血症、Paget病、II型糖尿病药物的治疗目标，目前正在积极研究其他代表全球主要健康负担的疾病。尽管投入了巨额资金，但目前还没有作用于这些受体的口服药物。这说明人们对它们的运作方式缺乏机械性的理解。我的研究重点是解决这个问题，以及如何利用这些受体来设计和识别更好的药物。

Family B GPCRs are therapeutic targets for drugs treating osteoporosis, hypercalcaemia, Paget’s disease, type II diabetes and are being actively pursued for other diseases that represent major global health burdens. Despite huge financial input, there are no orally available drugs that act on these receptors. This speaks to a lack of mechanistic understanding of how they work. My research focuses on addressing this question and how to exploit these receptors to design and identify better drugs.